140 related articles for article (PubMed ID: 22966291)
1. High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.
Umemura S; Shirane M; Takekoshi S; Tokuda Y; Mori K; Osamura RY
Oncol Lett; 2010 Mar; 1(2):261-266. PubMed ID: 22966291
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
3. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
[TBL] [Abstract][Full Text] [Related]
4. c-Met and ERĪ² expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
5. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
[TBL] [Abstract][Full Text] [Related]
6. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
7. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Andreetta C; Puppin C; Minisini A; Valent F; Pegolo E; Damante G; Di Loreto C; Pizzolitto S; Pandolfi M; Fasola G; Piga A; Puglisi F
Ann Oncol; 2009 Feb; 20(2):265-71. PubMed ID: 18765464
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine.
Zhu Y; Li K; Zhang J; Wang L; Sheng L; Yan L
Transl Cancer Res; 2021 Mar; 10(3):1193-1203. PubMed ID: 35116447
[TBL] [Abstract][Full Text] [Related]
9. Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.
Tedeschi AL; Eslami Z; Garoufalis E; Saleh RR; Omeroglu A; Altinel G; Ait-Tihyaty M; Jean-Claude B; Mihalcioiu C
Onco Targets Ther; 2015; 8():911-9. PubMed ID: 25960662
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.
Karihtala P; Kauppila S; Soini Y; Arja-Jukkola-Vuorinen
BMC Cancer; 2011 Jun; 11():262. PubMed ID: 21693047
[TBL] [Abstract][Full Text] [Related]
11. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.
Kanapathy Pillai SK; Tay A; Nair S; Leong CO
BMC Clin Pathol; 2012 Sep; 12():18. PubMed ID: 23009686
[TBL] [Abstract][Full Text] [Related]
13. Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.
Sable M; Pai TD; Shet T; Patil A; Dhanavade S; Desai SB
Int J Surg Pathol; 2017 May; 25(3):230-237. PubMed ID: 27612858
[TBL] [Abstract][Full Text] [Related]
14. Glut-1 Expression Correlates with Basal-like Breast Cancer.
Hussein YR; Bandyopadhyay S; Semaan A; Ahmed Q; Albashiti B; Jazaerly T; Nahleh Z; Ali-Fehmi R
Transl Oncol; 2011 Dec; 4(6):321-7. PubMed ID: 22190995
[TBL] [Abstract][Full Text] [Related]
15. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer: disease entity or title of convenience?
Carey L; Winer E; Viale G; Cameron D; Gianni L
Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Ait-Tihyaty M; Rachid Z; Mihalcioiu C; Jean-Claude BJ
Breast Cancer Res Treat; 2012 May; 133(1):217-26. PubMed ID: 21915635
[TBL] [Abstract][Full Text] [Related]
18. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study.
Sousa B; Paredes J; Milanezi F; Lopes N; Martins D; Dufloth R; Vieira D; Albergaria A; Veronese L; Carneiro V; Carvalho S; Costa JL; Zeferino L; Schmitt F
Histol Histopathol; 2010 Aug; 25(8):963-74. PubMed ID: 20552547
[TBL] [Abstract][Full Text] [Related]
19. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
20. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients.
Tominaga T; Toi M; Ohashi Y; Abe O;
Clin Breast Cancer; 2002 Apr; 3(1):55-64. PubMed ID: 12020396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]